News
NVRO
12.27
-0.20%
-0.03
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
Nevro Corp. Will release its financial results for the first quarter of 2024 after the market closes on Tuesday, May 7, 2024. The company will also host a conference call to discuss the financial results. Nevro is a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain.
PR Newswire · 1d ago
Nevro (NVRO) Price Target Decreased by 5.65% to 18.16
NASDAQ · 1d ago
Nevro Is Maintained at Sector Perform by RBC Capital
Dow Jones · 2d ago
Nevro Price Target Cut to $16.00/Share From $18.00 by RBC Capital
Dow Jones · 2d ago
RBC Capital Maintains Sector Perform on Nevro, Lowers Price Target to $16
Benzinga · 2d ago
Weekly Report: what happened at NVRO last week (0408-0412)?
Weekly Report · 3d ago
NEVRO CORP <NVRO.N>: TRUIST SECURITIES CUTS TARGET PRICE TO $14 FROM $19
Reuters · 3d ago
NEVRO CORP <NVRO.N>: RBC CUTS TARGET PRICE TO $16 FROM $18
Reuters · 3d ago
Nevro Is Maintained at Neutral by Mizuho
Dow Jones · 04/11 11:48
Nevro Price Target Cut to $16.00/Share From $20.00 by Mizuho
Dow Jones · 04/11 11:48
Mizuho Maintains Neutral on Nevro, Lowers Price Target to $16
Benzinga · 04/11 11:38
NEVRO CORP <NVRO.N>: MIZUHO CUTS TARGET PRICE TO $16 FROM $20
Reuters · 04/11 11:37
Nevro Price Target Cut to $14.00/Share From $17.00 by Wells Fargo
Dow Jones · 04/08 12:47
Nevro Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 04/08 12:47
Wells Fargo Maintains Equal-Weight on Nevro, Lowers Price Target to $14
Benzinga · 04/08 12:37
NEVRO CORP. <NVRO.N>: WELLS FARGO CUTS TARGET PRICE TO $14 FROM $17
Reuters · 04/08 10:33
Weekly Report: what happened at NVRO last week (0401-0405)?
Weekly Report · 04/08 09:25
This Nevro Insider Increased Their Holding By 59% Last Year
Nevro Corp. Insiders bought US$172k worth of shares in the last year. The biggest insider purchase was by Shawn McCormick for US$22.88 per share. In the past year, Nevro insiders have bought more stock than they sold in the company. The company owns about 2.6% of Nevro Corp.'s shares. You can see the insider transactions at Nevro over the year.
Simply Wall St · 04/04 19:11
Where Nevro Stands With Analysts
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation system for the treatment of chronic pain. The company has an average 12-month price target of $18.0. Nevro has a positive revenue growth rate of 2.05% over the past year.
Benzinga · 04/03 17:01
Nevro Price Target Cut to $16.00/Share From $18.00 by Citigroup
Dow Jones · 04/03 16:07
More
Webull provides a variety of real-time NVRO stock news. You can receive the latest news about Nevro Corp through multiple platforms. This information may help you make smarter investment decisions.
About NVRO
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.